Showing 11 - 20 of 687,566
Introduction: In 2009, the Swedish pharmaceuticals market was reformed. One of the stated policy goals was to achieve … generic pharmaceuticals have been collected, and a log-linear regression model was used to estimate how the policy changes … supplying off-patent pharmaceuticals experienced a clear reduction in the price received for their products. …
Persistent link: https://www.econbiz.de/10011019147
name pharmaceuticals, while the results regarding generics are less clear. In the empirical part of the paper, the … introduction of the substitution reform in the Swedish pharmaceuticals market in October 2002 is used as a natural experiment … lowered the price of both brand name- and generic pharmaceuticals. …
Persistent link: https://www.econbiz.de/10005419303
price of brand name pharmaceuticals, while the results regarding generics are less clear. In the empirical part of the paper …, the introduction of the substitution reform in the Swedish pharmaceuticals market in October 2002 is used as a natural … reform has lowered the price of both brand name- and generic pharmaceuticals. …
Persistent link: https://www.econbiz.de/10005652004
In October 2002 a substitution reform was introduced in the Swedish Pharmaceuticals market. In this note, the effects …
Persistent link: https://www.econbiz.de/10009150730
With the Hatch-Waxman Act of 1984, the FDA included an unchallengeable exclusivity period for newly approved drugs, independent of patents. This potentially generates an incentive for firms to strategically delay the introduction of new versions (reformulations) of drugs until just before patent...
Persistent link: https://www.econbiz.de/10014135034
generic pharmaceuticals during the first four years after the reform. The results also show that the price adjustment was not …
Persistent link: https://www.econbiz.de/10005197987
This article provides a tractable model of inter-temporal price-discrimination by heterogeneous firms, imperative for our understanding of advance purchase markets in the wake of entry. The pricing schedule of a more efficient entrant is found to differ systematically from the pricing schedule...
Persistent link: https://www.econbiz.de/10012548537
This paper examines competition between generic and brand-name drugs in the regulated Spanish pharmaceutical market. A nested logit demand model is specified for the three most consumed therapeutic subgroups in Spain: statins (anticholesterol), selective serotonin reuptake inhibitors...
Persistent link: https://www.econbiz.de/10013124302
monthly data for pharmaceuticals prescribed from 1997 to 2005. The simulation indicates that the regulation of prices is …
Persistent link: https://www.econbiz.de/10013124304
Pharmaceutical markets experience the entry of numerous generic firms upon expiration of the brand firm's patent. In this paper, we take a close look at competition among the generic entrants during the first three years after patent expiration and examine whether there is a first mover...
Persistent link: https://www.econbiz.de/10012709667